Evotec SE (EVO) Net Income towards Common Stockholders (2009 - 2025)
Evotec SE (EVO) reported Net Income towards Common Stockholders of -$120.4 million for Q4 2025, up 42.5% on a YoY basis from -$84.5 million in Q4 2024, and down 240274.03% sequentially from -$50074.1 in Q3 2025.
Evotec SE (EVO) Net Income towards Common Stockholders (2009 - 2025) Analysis & Trends
Evotec SE (EVO) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$120.4 million in Q4 2025.
- For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 42.5% year-over-year to -$120.4 million; the trailing twelve-month figure through Mar 2026 stood at -$120.4 million (up 42.49% YoY), and the FY2025 full-year result was -$120.5 million, up 42.49% from the prior year.
- Net Income towards Common Stockholders declined to -$120.4 million in Q4 2025, from -$50074.1 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $246.3 million in Q4 2021 to a low of -$209.3 million in Q4 2024.
- A 5-year average of -$23.5 million and a median of -$29810.4 in 2022 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders surged 9714.16% in 2021 and sank 240.15% in 2024, its largest moves.
- Tracing EVO's Net Income towards Common Stockholders over 5 years: stood at $246.3 million in 2021, then tumbled by 172.84% to -$179.4 million in 2022, then soared by 49.69% to -$90.2 million in 2023, then sank by 131.96% to -$209.3 million in 2024, then surged by 42.5% to -$120.4 million in 2025.
- Business Quant data shows EVO's Net Income towards Common Stockholders at -$120.4 million in Q4 2025, -$50074.1 in Q3 2025, and -$209.3 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.81 Bn | 32.07 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.51 Bn | 23.45 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 23.19 Bn | 21.04 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.47 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.72 Bn | 16.40 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.56 Bn | 12.13 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Evotec SE | 345.39 Mn | 344.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -120.37 Mn |
| Sep 30, 2025 | -50,074.14 |
| Dec 31, 2024 | -209.31 Mn |
| Sep 30, 2024 | -59,430.15 |
| Dec 31, 2023 | -90.24 Mn |
| Sep 30, 2023 | 42,406.04 |
| Jun 30, 2023 | -13,888.14 |
| Dec 31, 2022 | -179.36 Mn |
| Sep 30, 2022 | 47,666.17 |
| Jun 30, 2022 | -29,810.36 |
| Mar 31, 2022 | -82,202.26 |
| Dec 31, 2021 | 246.25 Mn |
| Sep 30, 2021 | 158,344.09 |
| Jun 30, 2021 | 72,274.35 |
| Mar 31, 2021 | 63,571.06 |
| Dec 31, 2020 | 7.48 Mn |
| Sep 30, 2020 | -1,646.99 |
| Dec 31, 2019 | 42.23 Mn |
| Sep 30, 2010 | 170,478.98 |
| Jun 30, 2010 | 151,033.82 |